The Nasdaq Biotech index has grown about 50 percent since Yellen's valuation comments. Superarando por mucho el desempeño de los indices composite y S&P500 , this boom is due primarily to the pharmaceutical companies who have monopolized the attention of investors the past few months, beyond the debate of whether exist a bubble formation the Nasdaq Biotechnology Index It ought to correct their overbought at least 6% as it has done in later months
Biotechs could be the early warning for stocks http://cnb.cx/1N9Sg68
The uncertainty caused by the excessive increase in the valuation of shares, based on the promises of extraordinary cash flows through products that are still in experimental stages of research and development is an increasingly risky. The appetite for higher-yielding assets and high risk is associated with the availability of liquidity injected by central banks in the market at low interest rates, when a change occurs in this scenario the liquidation of long positions will result in a significant correction that all expect.